AstraZeneca Pushes Deeper into CDx Space with New Collaboration

AstraZeneca is making a bigger push into the companion diagnostics space. The pharmaceutical company is teaming up with Shanghai, China-based Amoy Diagnostics to develop assays.

The companies are working on two initial projects. The first is the co-development of a CDx to identify prostate cancer patients with Homologous Recombination Repair (HRR) gene mutations in China, the EU and Japan.